Nanobiotix S.A.
Business
Nanobiotix S.A. is a late-stage clinical biotechnology company that develops physics-based, nanoparticle therapies to improve cancer and CNS treatment outcomes. Its main product candidates and platforms include NBTXR3 (a radiotherapy-activated hafnium oxide nanoparticle radioenhancer), Curadigm (nanoprimer technology to improve therapeutic index), and Oocuity (nanomaterials for CNS disorders). The company operates through clinical development, manufacturing partnerships and strategic licensing/collaboration arrangements. It advances global clinical programs and distributes through clinical centers and commercial partners across the United States, Europe, Asia and other international markets.
Summary from filing dated 2025-04-02
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-24.00M |
| Total assets | $67.76M |
| Total liabilities | $152.24M |
| Stockholders' equity | — |
| Operating cash flow | — |